Plain-English translation of NCT05469893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new immunotherapy drug, can better treat high-risk smoldering multiple myeloma than current standard treatment. Smoldering myeloma is an early stage of multiple myeloma, a blood cancer affecting plasma cells. The study will compare how well the new medication works compared to the combination of two established drugs ( and ).
High-risk smoldering myeloma is a serious condition that often progresses to active cancer within a few years. Doctors want to find better treatment options that can control the disease earlier and improve outcomes for patients before it becomes fully active.
You likely qualify if…
You likely don't qualify if…
You will first go through a screening phase with blood tests and bone marrow evaluation. If you qualify, you will be randomly assigned to receive either the new immunotherapy medication or the standard combination treatment. You will take your assigned medication in 28-day cycles for up to 24 months, coming to the clinic regularly for blood tests, physical exams, and check-ins to monitor how well the treatment is working and watch for side effects. The study includes an initial safety phase where the first few participants receive lower doses of the new medication to make sure it is safe before other participants join.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States